Cue Biopharma (NASDAQ:CUE) Trading 19.9% Higher – Time to Buy?

Cue Biopharma, Inc. (NASDAQ:CUE) rose 19.9% during mid-day trading on Monday . The stock traded as high as $30.75 and last traded at $30.43. Approximately 163,488 shares traded hands during mid-day trading, an increase of 112% from the average daily volume of 76,983 shares. The stock had previously closed at $25.39.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Weiss Ratings raised shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded Cue Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Cue Biopharma Stock Performance

The company has a 50 day moving average of $61.57 and a 200 day moving average of $210.46. The stock has a market capitalization of $119.03 million, a price-to-earnings ratio of -5.07 and a beta of 2.52.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.30) by $2.22. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The company had revenue of $5.69 million for the quarter, compared to analysts’ expectations of $2.50 million.

Institutional Trading of Cue Biopharma

Large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its holdings in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Cue Biopharma during the 3rd quarter worth approximately $62,000. Stifel Financial Corp grew its position in shares of Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc grew its position in shares of Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares in the last quarter. Finally, Boothbay Fund Management LLC increased its holdings in shares of Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after purchasing an additional 93,333 shares during the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.